Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BENSALEM, Pa., July 23, 2021 /PRNewswire/ -- Law Offices of Howard G.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)

Affimed

GT Biopharma Inc

Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%

It would likely take until mid-2023 for the FDA to approve Covaxin. By that time, the shot could be obsolete.

Ocugen Likely Can't Get a Boost From the FDA Until 2023

New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

Rosen, Globally Respected Investor Counsel, Encourages Ocugen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - OCGN

Moderna

Novavax

QuidelOrtho Corp

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today appeared first on InvestorPlace.

Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today

The delta variant is lifting the tide of companies associated with COVID testing and prevention.

Why Shares of Ocugen Climbed Today

NEW YORK, July 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 21-cv-03182, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Ocugen securities between February 2, 2021, and June 10, 2021, inclusive (the "Class Period"), seeking to recover damages for violations of the federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. and Certain Officers - OCGN

New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGEN).Shareholders who purchased shares of OCGN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ocugen-inc-loss-submission-form/?id=17730&from=5

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Ocugen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2021 - (OCGN)

New York, New York--(Newsfile Corp. - July 16, 2021) - WHY: New York, N.Y., July 16, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment...

OCGN ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - OCGN

There won't be a market for COVAXIN in the US as vaccination rates continue moving up. Without a successful US launch of COVAXIN, OCGN stock doesn't even warrant the price of a dollar.

Ocugen Stock Is Well Past Its Expiration Date and It Shows

Academy Sports and Outdoors

Blink Charging

Carver Bancorp

GoodRx Holdings

GEO Group

MicroStrategy Incorporated

Root

SmileDirectClub

We're taking a look at some of the lesser-known short-squeeze stocks popular with retail investors that should be on your radar. The post 9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investors appeared first on InvestorPlace.

9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investors

San Diego, California--(Newsfile Corp. - July 15, 2021) - The Ocugen, Inc. class action lawsuit charges Ocugen, Inc. (NASDAQ: OCGN) and certain of its top executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Ocugen securities between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"). The Ocugen class action lawsuit (Nicanor v. Ocugen, Inc., No. 21-cv-02725) was commenced on June 17, 2021 in the...

OCGN SHAREHOLDER ALERT: Shareholders With Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit

Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling submission of its regulatory application for its COVID-19 vaccine candidate Covaxin in Canada.

Why Ocugen Shares Are Rallying Today

MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it had initiated a rolling submission to Health Canada for COVAXIN™, the company's candidate vaccine against COVID-19, which it is co-developing with Bharat Biotech International Ltd. for the U.S. and Canadian markets. This follows the release by Bharat Biotech of Phase 3 clinical trial results, which demonstrated efficacy and safety in nearly 25,800 adults.

Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™

Astronics

Manchester United

Carrols Restaurant Group

Toxic stocks are vulnerable to external shocks, burdened with high debt and bound to result in loss for investors over time. Discard such stocks from your portfolio right away to avoid losses.

Sell These 4 Toxic Stocks to Avoid Losing Money Overnight

SAN DIEGO--(BUSINESS WIRE)-- #OCGNstock--The suit alleges defendants issued false statements concerning Ocugen business and prospects, resulting in its stock trading at inflated prices.

OCGN INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit

The big jump resulted from the company's partnership with Bharat Biotech to commercialize COVID-19 vaccine Covaxin.

Why Ocugen Stock Skyrocketed 339% in the First Half of 2021

New York, New York--(Newsfile Corp. - July 13, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Ocugen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocugen, Inc. - OCGN

SAN DIEGO, July 12, 2021 /PRNewswire/ -- The Ocugen, Inc. class action lawsuit charges Ocugen, Inc. (NASDAQ: OCGN) and certain of its top executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Ocugen securities between February 2, 2021 and June 10, 2021, inclusive (the "Class Period").  The Ocugen class action lawsuit (Nicanor v.

OCUGEN INVESTOR NOTICE: Investors With Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN

New York, New York--(Newsfile Corp. - July 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...

ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors With Losses Over $500K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - OCGN

While the Delta variant Covid-19 strain threatens the population, OCGN stock investors can count on Ocugen to advance its vaccine candidate. The post Ocugen's Recent Vaccine Efficacy Results Should Have Traders Cheering appeared first on InvestorPlace.

Ocugen's Recent Vaccine Efficacy Results Should Have Traders Cheering

NEW YORK, July 10, 2021 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

OCGN INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - OCGN

Investors may be getting concerned about how long it may take for COVID-19 vaccine Covaxin to get approved.

Why Shares of Ocugen Are Dropping Today

BioNTech SE

Inovio Pharmaceuticals

Stock markets moved slightly higher despite general worries.

With COVID-19 Variant Threats Rising, Why Are Vaccine Stocks Falling?

Phase 3 data on Covaxin wasn't outstanding, and there are indications that demand for additional vaccines in the U.S. and Canada will be low for some time. OCGN remains a good stock to short.

News for Ocugen, Inc. Stock (OCGN)